RxDoctor Payments Data

Jessica Sarkisian, APRN

Nurse Practitioner · East Haven, CTNPI 1952076564

Payments from drug & device makers

$1,840in general payments, 2019–2025

Across 71 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$730
  • Otsuka America Pharmaceutical, Inc.$648
  • Acadia Pharmaceuticals Inc$220
  • Avanir Pharmaceuticals, Inc.$118
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$73
  • Optinose US, Inc.$23
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$1,840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,840 in reported general payments places this provider in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

See all nurse practitioner providers in Connecticut

Medicare billing

Part B allowed, 2024
$87,048
Medicare patients
291
Services billed
964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate19$78,984
RexultiBrexpiprazole13$6,600
Trazodone Hcl285$3,433
Mirtazapine166$2,712
Lorazepam66$1,523
Duloxetine Hcl26$1,040
Sertraline Hcl95$1,019
Memantine Hcl17$937
Escitalopram Oxalate84$839
Risperidone47$639
Bupropion XlBupropion Hcl35$483
Buspirone Hcl34$454
Bupropion Hcl SrBupropion Hcl23$371
Clonazepam27$356
Alprazolam16$329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$730$78,98419 claims
Otsuka America Pharmaceutical, Inc.Rexulti$648$6,60013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 nurse practitioner providers in Connecticut.

Other nurse practitioner in East Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →